The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications

被引：10
作者：
Hargadon, K. M. [1 ]
机构：
[1] Hampden Sydney Coll, Dept Biol, Hargadon Lab, Hampden Sydney, VA 23943 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 06期
关键词：
PD-1; BLOCKADE; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; STING ACTIVATION; DNA METHYLATION; DENDRITIC CELLS; I INTERFERONS; SUPPRESSION;
D O I：
10.1111/bjd.20608
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Immune checkpoint blockade (ICB) therapy has achieved unprecedented success in the treatment of metastatic melanoma, though its efficacy is often limited by innate and acquired mechanisms of resistance. Type I and type II interferons (IFNs) act as key determinants of checkpoint blockade therapeutic outcome, and tumour-intrinsic and -extrinsic factors that disrupt IFN activity confer resistance to various checkpoint inhibitors. This review highlights our current understanding of the mechanisms by which tumours disrupt IFN function in the context of ICB, and it discusses therapeutic strategies to overcome these mechanisms of resistance and improve the clinical reach of ICB therapy in patients with melanoma.
引用
收藏
页码：1095 / 1104
页数：10
相关论文
共 80 条
  • [21] Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
    Grasso, Catherine S.
    Tsoi, Jennifer
    Onyshchenko, Mykola
    Abril-Rodriguez, Gabriel
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    Champhekar, Ameya
    Medina, Egmidio
    Torrejon, Davis Y.
    Shin, Daniel Sanghoon
    Phuong Tran
    Kim, Yeon Joo
    Puig-Saus, Cristina
    Campbell, Katie
    Vega-Crespo, Agustin
    Quist, Michael
    Martignier, Christophe
    Luke, Jason J.
    Wolchok, Jedd D.
    Johnson, Douglas B.
    Chmielowski, Bartosz
    Hodi, Stephen
    Bhatia, Shailender
    Sharfman, William
    Urba, Walter J.
    Slingluff, Craig L., Jr.
    Diab, Adi
    Haanen, John B. A. G.
    Algarra, Salvador Martin
    Pardoll, Drew M.
    Anagnostou, Valsamo
    Topalian, Suzanne L.
    Velculescu, Victor E.
    Speiser, Daniel E.
    Kalbasi, Anusha
    Ribas, Antoni
    [J]. CANCER CELL, 2020, 38 (04) : 500 - +
  • [22] Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X
  • [23] Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Hamid, O.
    Robert, C.
    Daud, A.
    Hodi, F. S.
    Hwu, W. J.
    Kefford, R.
    Wolchok, J. D.
    Hersey, P.
    Joseph, R.
    Weber, J. S.
    Dronca, R.
    Mitchell, T. C.
    Patnaik, A.
    Zarour, H. M.
    Joshua, A. M.
    Zhao, Q.
    Jensen, E.
    Ahsan, S.
    Ibrahim, N.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 582 - 588
  • [24] Genomic and transcriptional changes in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunotherapy in melanoma patients
    Hargadon, Kristian
    Gyorffy, Balazs
    McGee, Taylor J.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (12) : 1099 - 1103
  • [25] Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
    Hargadon, Kristian M.
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 374 - 411
  • [26] Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
    Hargadon, Kristian M.
    Johnson, Coleman E.
    Williams, Corey J.
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 29 - 39
  • [27] Strategies to improve the efficacy of Dendritic Cell-Based immunotherapy for Melanoma
    Hargadon, Kristian M.
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [28] RIG-I activation is critical for responsiveness to checkpoint blockade
    Heidegger, Simon
    Wintges, Alexander
    Stritzke, Florian
    Bek, Sarah
    Steiger, Katja
    Koenig, Paul-Albert
    Goettert, Sascha
    Engleitner, Thomas
    Oellinger, Rupert
    Nedelko, Tatiana
    Fischer, Julius C.
    Makarov, Vladimir
    Winter, Christof
    Rad, Roland
    van den Brink, Marcel R. M.
    Ruland, Juergen
    Bassermann, Florian
    Chan, Timothy A.
    Haas, Tobias
    Poeck, Hendrik
    [J]. SCIENCE IMMUNOLOGY, 2019, 4 (39)
  • [29] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
    Hodi, F. Stephen
    O'Day, Steven J.
    McDermott, David F.
    Weber, Robert W.
    Sosman, Jeffrey A.
    Haanen, John B.
    Gonzalez, Rene
    Robert, Caroline
    Schadendorf, Dirk
    Hassel, Jessica C.
    Akerley, Wallace
    van den Eertwegh, Alfons J. M.
    Lutzky, Jose
    Lorigan, Paul
    Vaubel, Julia M.
    Linette, Gerald P.
    Hogg, David
    Ottensmeier, Christian H.
    Lebbe, Celeste
    Peschel, Christian
    Quirt, Ian
    Clark, Joseph I.
    Wolchok, Jedd D.
    Weber, Jeffrey S.
    Tian, Jason
    Yellin, Michael J.
    Nichol, Geoffrey M.
    Hoos, Axel
    Urba, Walter J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) : 711 - 723
  • [30] ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
    Hu, Mengjie
    Zhou, Min
    Bao, Xuhui
    Pan, Dong
    Jiao, Meng
    Liu, Xinjian
    Li, Fang
    Li, Chuan-Yuan
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (03)
12345678